Overview

An Open, Exploratory Clinical Study of CM336 in the Treatment of Immune Thrombocytopenia

Status:
RECRUITING
Trial end date:
2027-01-31
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of CM336 in the treatment of refractory adult primary immune thrombocytopenia
Phase:
PHASE2
Details
Lead Sponsor:
Institute of Hematology & Blood Diseases Hospital, China